Literature DB >> 21346034

New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview.

Robert J Motzer1.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21346034      PMCID: PMC3868198          DOI: 10.1634/theoncologist.2011-S2-01

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  18 in total

Review 1.  Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  B Escudier; V Kataja
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

2.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

3.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

4.  Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.

Authors:  Arie S Belldegrun; Tobias Klatte; Brian Shuch; Jeffrey C LaRochelle; David C Miller; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Jean B Dekernion; Allan J Pantuck
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

Review 5.  Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.

Authors:  Dale R Shepard; Jorge A Garcia
Journal:  Expert Rev Anticancer Ther       Date:  2009-06       Impact factor: 4.512

6.  Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Staehler; Sylvie Negrier; Christine Chevreau; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Sibyl Anderson; Gloria Hofilena; Minghua Shan; Carol Pena; Chetan Lathia; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

8.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

9.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.

Authors:  Robert J Motzer; Bernard Escudier; Stéphane Oudard; Thomas E Hutson; Camillo Porta; Sergio Bracarda; Viktor Grünwald; John A Thompson; Robert A Figlin; Norbert Hollaender; Gladys Urbanowitz; William J Berg; Andrea Kay; David Lebwohl; Alain Ravaud
Journal:  Lancet       Date:  2008-07-22       Impact factor: 79.321

Review 10.  EORTC-GU group expert opinion on metastatic renal cell cancer.

Authors:  Theo M de Reijke; Joaquim Bellmunt; Hein van Poppel; Sandrine Marreaud; Matti Aapro
Journal:  Eur J Cancer       Date:  2009-01-20       Impact factor: 9.162

View more
  17 in total

Review 1.  Targeted therapies in metastatic renal cell carcinoma: overview of the past year.

Authors:  Marine Gross-Goupil; Christophe Massard; Alain Ravaud
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma.

Authors:  I Yildiz; F Sen; L Kilic; M Ekenel; C Ordu; I Kilicaslan; E Darendeliler; H M Tunc; U Varol; S Bavbek; M Basaran
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

3.  The Choi response criteria for inferior vena cava tumor thrombus in renal cell carcinoma treated with targeted therapy.

Authors:  Taekmin Kwon; Jae-Lyun Lee; Jeong Kon Kim; Dalsan You; In Gab Jeong; Cheryn Song; Hanjong Ahn; Choung-Soo Kim; Jun Hyuk Hong
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-20       Impact factor: 4.553

4.  Autocrine MCP-1/CCR2 signaling stimulates proliferation and migration of renal carcinoma cells.

Authors:  Christoph Küper; Franz-Xaver Beck; Wolfgang Neuhofer
Journal:  Oncol Lett       Date:  2016-07-18       Impact factor: 2.967

5.  Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?

Authors:  Pierre Bigot; Tarek Fardoun; Jean Christophe Bernhard; Evanguelos Xylinas; Julien Berger; Morgan Rouprêt; Jean-Baptiste Beauval; Samuel Lagabrielle; Souhil Lebdai; Myriam Ammi; Hervé Baumert; Bernard Escudier; Nicolas Grenier; Jean-François Hétet; Jean-Alexandre Long; Philippe Paparel; Nathalie Rioux-Leclercq; Michel Soulié; Abdel-Rahmène Azzouzi; Karim Bensalah; Jean-Jacques Patard
Journal:  World J Urol       Date:  2013-04-27       Impact factor: 4.226

6.  The accuracy of renal tumor biopsy: analysis from a national prospective study.

Authors:  J C Bernhard; P Bigot; G Pignot; H Baumert; L Zini; H Lang; M Crepel; P Monod; L Salomon; L Bellec; M Roupret; M Schneider; E Xylinas; P Paparel; F Bruyere; J Berger; J P Ansieau; P Gimel; F Salome; C Castagnola; C Pfister; J M Legraverend; M O Timsit; L Le Pellec; J L Auberget; E Rolland; R Mallet; A Mejean; J J Patard
Journal:  World J Urol       Date:  2014-11-06       Impact factor: 4.226

7.  Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.

Authors:  Ai-Ping Zhou; Yuxian Bai; Yan Song; Hong Luo; Xiu-Bao Ren; Xiuwen Wang; Benkang Shi; Cheng Fu; Ying Cheng; Jiyan Liu; Shukui Qin; Jun Li; Hanzhong Li; Xianzhong Bai; Dingwei Ye; Jinwan Wang; Jianhui Ma
Journal:  Oncologist       Date:  2019-03-22

8.  An unusual metastatic renal cell carcinoma with maintained complete response to sunitinib treatment.

Authors:  Luis Chara; Beatriz Rodríguez; Esther Holgado; Natalia Ramírez; Isabel Fernández-Rañada; Nicolás Mohedano; Alberto Arcediano; Inés García; Javier Cassinello
Journal:  Case Rep Oncol       Date:  2011-12-07

9.  NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells.

Authors:  Christoph Küper; Franz-Xaver Beck; Wolfgang Neuhofer
Journal:  Front Physiol       Date:  2014-08-08       Impact factor: 4.566

10.  Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy.

Authors:  T Raja
Journal:  Ecancermedicalscience       Date:  2014-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.